The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

The lawmakers also say that a Cures 2.1 push should include an update to the government’s clinical trial website to enable ... data submitted by each pharmaceutical company and explain how ...

Eli Lilly has launched a new website-based access ... diabetes and migraine drugs, respectively, via telehealth providers 9amHealth and Cove. According to the company, it allows “consistent ...

Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...

Lilly seeks to protect interests in compounded ... and facilities can keep selling cheaper versions of the company's weight-loss drug Zepbound and diabetes medicine Mounjaro, which have the ...

WASHINGTON — Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment.